Abivax SA (ABVX) Income Statement
ABVX 2025 at a glance
Fiscal year ended December 31, 2025 · eurosABVX revenue and net income
ABVX profit margins
ABVX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −109.5% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABVX income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €0 | €10.8M | €4.6M | €4.6M | €37,000 | €63,000 | €2,000 | €18,000 | €10,000 | €127,000 |
| Cost of revenue | €1.0M | €0 | €707,000 | €50.8M | €45.5M | €33.8M | €28.2M | €15.4M | €14.5M | €14.6M |
| Gross profit | −€1.0M | €10.8M | €4.6M | −€50.8M | −€45.5M | −€33.8M | −€28.2M | −€15.4M | −€14.5M | −€14.5M |
| Research & development | €177.8M | €146.5M | €103.2M | €48.3M | €47.8M | €34.5M | €29.0M | €15.9M | €10.8M | €15.5M |
| Sales, general & admin | €72.9M | €38.0M | €28.1M | €7.5M | €5.6M | €5.6M | €4.9M | €4.3M | €3.8M | €3.6M |
| Total operating expenses | €246.1M | €173.0M | €127.4M | €14.1M | −€4.1M | €4.2M | €5.1M | €3.7M | −€347,000 | €3.7M |
| Operating income | −€246.1M | −€173.0M | −€127.4M | −€64.8M | −€41.4M | −€38.0M | −€33.3M | −€19.1M | −€14.2M | −€18.2M |
| Interest income | €5.8M | €9.0M | €2.8M | €128,000 | €84,000 | €0 | €14,000 | — | — | — |
| Interest expense | €28.5M | €12.4M | €13.8M | €6.9M | €3.6M | €2.1M | €1.6M | €469,000 | €31,000 | €42,000 |
| Income before taxes | −€330.3M | −€176.2M | −€147.7M | −€60.7M | −€42.5M | −€40.1M | −€34.9M | −€19.8M | −€14.1M | −€18.0M |
| Income taxes | €5.8M | — | −€4.5M | −€4.5M | −€4.2M | −€2.6M | −€4.3M | −€4.0M | −€2.7M | −€3.5M |
| Net income | −€336.1M | −€176.2M | −€147.7M | −€60.7M | −€42.5M | −€37.6M | −€30.6M | −€15.8M | −€11.2M | −€14.3M |
| EBITDA | −€300.7M | −€162.7M | −€133.2M | −€53.3M | −€38.6M | −€38.0M | −€33.2M | −€19.2M | −€14.0M | −€17.9M |
| Gross margin | — | 100.0% | 99.0% | −1,107.7% | −123,018.9% | −53,623.8% | −1,409,300.0% | −85,327.8% | −144,970.0% | −11,431.5% |
| Operating margin | — | −1,602.9% | −2,756.5% | −1,414.7% | −111,891.9% | −60,330.2% | −1,664,800.0% | −106,155.6% | −141,500.0% | −14,359.1% |
| Net margin | — | −1,633.1% | −3,197.1% | −1,325.3% | −114,735.1% | −59,604.8% | −1,531,700.0% | −87,905.6% | −112,230.0% | −11,266.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 | €2.0M | €0 | €7.4M | €0 | €3.4M | €0 | €2.3M | €2.2M |
| Cost of revenue | — | — | €1.0M | — | €0 | — | €0 | — | €0 | — | €378,000 | €329,000 |
| Gross profit | — | — | −€3.0M | — | €2.0M | — | €7.4M | — | €3.4M | — | €2.3M | €2.2M |
| Research & development | €58.3M | €49.5M | €44.4M | €55.4M | €38.6M | €39.3M | €39.3M | €43.3M | €28.9M | €35.7M | €70.6M | €32.6M |
| Sales, general & admin | €27.0M | €8.0M | €27.7M | €27.3M | €8.9M | €8.9M | €8.7M | €8.2M | €11.7M | €10.1M | €21.5M | €6.6M |
| Total operating expenses | €84.1M | €56.2M | €199.6M | €80.7M | €46.5M | €47.2M | €47.2M | €50.2M | €35.3M | €44.7M | €92.1M | €39.2M |
| Operating income | −€84.1M | −€56.2M | −€199.6M | −€80.7M | −€46.5M | −€47.2M | −€47.2M | −€50.2M | −€35.3M | −€44.7M | −€92.5M | −€39.5M |
| Interest income | €1.3M | €769,000 | €807,000 | €3.5M | €319,000 | €1.1M | €1.6M | €2.2M | €2.4M | €2.8M | — | — |
| Interest expense | €730,000 | €2.5M | €15.3M | €4.2M | €3.5M | €4.5M | €4.5M | €4.7M | €3.8M | €2.4M | €5.7M | €14.7M |
| Income before taxes | −€123.5M | −€48.2M | −€281.8M | −€153.4M | −€48.4M | −€52.4M | −€52.4M | −€55.2M | −€38.8M | −€42.9M | −€98.0M | −€54.2M |
| Income taxes | −€6.1M | — | €5.8M | — | — | — | — | — | — | — | −€2.3M | −€2.2M |
| Net income | −€117.4M | −€48.5M | −€287.7M | −€153.4M | −€48.4M | −€52.4M | −€52.4M | −€55.2M | −€38.8M | −€42.9M | −€95.8M | −€52.0M |
| EBITDA | −€122.4M | −€45.3M | −€256.5M | −€148.9M | −€44.6M | — | −€47.6M | — | −€34.6M | — | −€92.1M | −€39.2M |
| Gross margin | — | — | — | — | 100.0% | — | 100.0% | — | 100.0% | — | 100.0% | 100.0% |
| Operating margin | — | — | — | — | −2,305.2% | — | −637.9% | — | −1,041.1% | — | −3,975.2% | −1,758.7% |
| Net margin | — | — | — | — | −2,400.3% | — | −707.8% | — | −1,142.7% | — | −4,118.1% | −2,311.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in ABVX's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABVX financial results
Abivax SA reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of €336.1 million. Figures are in euros, the currency of its financial statements.
See the ABVX stock overview for the latest quote and news, or the ABVX chart for price history and technical indicators.
ABVX income statement FAQ
Does Abivax SA have revenue?
Abivax SA reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Abivax SA profitable?
No. Abivax SA reported a net loss of €336.1 million in fiscal 2025.
How much does Abivax SA spend on research and development?
Abivax SA spent €177.8 million on research and development in fiscal 2025.
When does Abivax SA's fiscal year end?
Abivax SA's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.